SMOKE FREE SWEDEN: DANSKE RESTRIKTIONER PÅ NIKOTINPOSER VIL FÅ 150.000 TIL AT VENDE TILBAGE TIL RYGNING
6.10.2024 17:00:00 CEST | Business Wire | Pressemeddelelse
Et foreslået forbud mod ni ud af ti nikotinposer i Danmark vil være et massivt tilbageskridt i kampen mod tobak og vil tvinge titusindvis af tidligere rygere tilbage til dødelige cigaretter, advarer førende internationale eksperter i dag.
Reguleringer på sundhedsområdet, som vil blive fremlagt for Folketinget fredag den 11. oktober, vil begrænse nikotinniveauet i en nikotinpose til 9 mg – langt under internationale standarder og kun en brøkdel af nikotinniveauet i cigaretter.
Dr. Delon Human, en global ekspert i skadereduktion og leder af ”Smoke Free Sweden”, siger: "Nikotinposer er bevist at være et langt sikrere alternativ til cigaretter og hjælper millioner af rygere med at stoppe over hele verden.”
"Forslaget, som Folketinget skal behandle, vil forbyde 90 % af de poser, der aktuelt bruges i Danmark, hvilket efterlader rygerne med valget mellem de få tilbageværende poser eller cigaretter, der indeholder 85 % mere nikotin.
"Det er ikke svært at forudsige, hvilket valg de vil ende med at træffe. Rygere, der overvejer at stoppe, vil blive nægtet et levedygtigt og sikrere alternativ, mens størstedelen af de 153.000 nuværende brugere af nikotinposer vil blive presset tilbage til cigaretter.
"At gøre den farligste måde at indtage nikotin på til den mest attraktive er simpelthen ulogisk og et massivt tilbageskridt i den fortsatte kamp mod tobakkens dødelige konsekvenser."
Danmarks naboland Sverige har vist, at en progressiv tilgang til skadesreducerende røgfrie nikotinprodukter er den bedste vej til at udrydde rygning og de sundhedskonsekvenser, som følger med.
Sverige har oplevet et ekstraordinært fald i antallet af rygere på 55 % over det seneste årti og er på nippet til officielt at blive erklæret røgfrit efter WHO’s målsætning. Sammenlignet med resten af EU har Sverige nu 44 % færre tobaksrelaterede dødsfald og en 41 % lavere kræftrate.
Sveriges succes tilskrives den udbredte brug af orale nikotinprodukter med forskellige nikotinstyrker og smagsvarianter samt regeringens politik med at lægge højere afgifter på cigaretter end på røgfrie nikotinprodukter.
Det danske forslag har til hensigt at forbyde de lange cigaretter, som i øjeblikket bruges af en tredjedel af rygerne, samtidig med at nikotinindholdet i poser begrænses.
"Forbuddet mod 30 % af cigaretterne på markedet burde være en stor mulighed for at opmuntre rygere til at skifte til sikrere alternativer som nikotinposer," siger Dr. Human. "I stedet forsøger forslagene at gøre poser ineffektive og mindre tiltalende end cigaretter.
"Som i Sverige bør den danske regering anerkende den vigtige rolle, disse skadesreducerede nikotinprodukter spiller i at hjælpe rygere med at overgå fra røgtobak og gøre sikrere alternativer tilgængelige, acceptable og til at betale."
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20241006970721/da/
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Boyd Watterson Global Names John Creswell Global Chief Client Officer to Accelerate Global Growth and Client Engagement23.7.2026 15:00:00 CEST | Press release
Veteran investment management executive will lead global sales, client engagement and marketing as Boyd Watterson Global continues expanding its global alternatives platform across real estate, infrastructure, and debt strategies. Boyd Watterson Global today announced the appointment of John Creswell as Global Chief Client Officer, a newly created senior leadership role that reflects the firm's continued investment in growth and its evolution into a leading global alternatives investment platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722823117/en/ John Creswell has joined Boyd Watterson Global as Global Chief Client Officer, a newly created role overseeing global sales, client engagement and marketing across the U.S., Europe and APAC. In this role, Creswell will oversee global sales, client engagement and marketing efforts across the United States, Europe and APAC, helping investors access the firm's capabilitie
Trulioo Launches AI Agent to Resolve Beneficial Ownership Where Global Registries Fall Short23.7.2026 15:00:00 CEST | Press release
Breakthrough AI agent reconstructs ownership for long-tail businesses and hard-to-reach jurisdictions while significantly increasing UBO coverage Trulioo, a global risk intelligence platform, today announced the UBO Discovery Agent, the newest layer in Trulioo's UBO Discovery capability inside its business risk and Know Your Business (KYB) verification workflow. AI is reshaping fraud, making it easier for bad actors to hide, and harder for companies to catch them. This makes the already tough job of verifying who actually owns a business even more difficult. Determining a business's ultimate beneficial owner is an ongoing, acute challenge for companies: registry coverage is inconsistent across countries, and even where registries exist, they typically record shareholders and directors of record (rather than the people actually in control). That data isn't simply outdated, it reflects a structural lag: ownership changes and time passes before the filing is made and processed, so a looku
Humanoid Raises $152 Million at $1.35 Billion Post-Money Valuation, Becoming Europe's First Pure-Play Humanoid Robotics Unicorn23.7.2026 15:00:00 CEST | Press release
Humanoid announces its Series A investment round, reaching a $1.35 billion valuation just two years after founding.It is the largest ever Series A for a humanoid-first robotics company in Europe, positioning Humanoid as the leading humanoid-first robotics unicorn in the UK and continental Europe.The new capital will accelerate Humanoid's next-generation robot development, commercial deployments with global industrial leaders, and evolution of the proprietary AI platform on the path toward general-purpose humanoids.The investment marks a defining moment for Europe's tech ecosystem, showing that globally competitive Physical AI companies can be built and scaled in Europe. Humanoid, a UK-based AI and robotics company building industrial humanoid robots, announced a $152 million Series A financing at a $1.35 billion post-money valuation. This funding brings the total amount raised to date to $270 million. The round was led by Prime Movers Lab, a venture capital firm focused on investments
Riskified Named to the CNBC World's Top Fintech Companies 2026 List23.7.2026 14:00:00 CEST | Press release
Payment category recognition marks Riskified's continued presence among the world's leading fintech innovators Riskified (NYSE: RSKD), a global leader in ecommerce fraud detection and risk intelligence, has been named to CNBC's World's Top Fintech Companies 2026 list, in the Payments category. The list, now in its fourth edition, is produced by CNBC in partnership with Statista Inc., the global statistics and industry ranking firm. It was announced on July 22, 2026, and is available on CNBC's website. This is Riskified's second time making the list. The company previously earned this recognition in 2024, reinforcing its position in the ecommerce fraud and risk intelligence sector and underscoring its ongoing success in empowering businesses to grow revenue and profitability by mitigating risk through its AI-powered platform. CNBC and Statista's ranking covers the top 500 companies across eight fintech segments — Payments, Neobanking, Alternative Financing, Wealth Technology, Digital As
Azafaros Completes Enrollment of Phase 3 (NAVIGATE) Study Evaluating Nizubaglustat for the Treatment of Patients with GM1/GM2 Gangliosidoses23.7.2026 13:00:00 CEST | Press release
NAVIGATE comprises two pivotal Phase 3 studies investigating nizubaglustatRecruitment completed in Phase 3 registrational study in patients with late-infantile and juvenile GM1/GM2 gangliosidosesEnrollment in Niemann-Pick type C disease (NPC) Phase 3 study is ongoingTopline data from GM1/GM2 gangliosidoses Phase 3 study is anticipated in early 2028 Azafaros, a private company building a portfolio of disease-modifying therapeuticsto become a leader in lysosomal storage disorders (LSDs) focused on addressing neurological symptoms, today announced the completion of patient recruitment in its Phase 3 study evaluating nizubaglustat for the treatment of GM1/GM2 gangliosidoses. “Completing enrollment in our Phase 3 GM1/GM2 study is a significant step toward potentially bringing nizubaglustat to patients and families living with these devastating neurodegenerative diseases," said Stefano Portolano, Chief Executive Officer at Azafaros. "We are deeply grateful to the patients, caregivers, invest
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum